Maze Therapeutics Raises $191M in Launch Funding

Maze Therapeutics, a San Francisco, CA-based company focused on translating genetic insights into new medicines, raised $191m in funding.

The round was led by Third Rock Ventures and ARCH Venture Partners, with participation from GV, Foresite Capital, Casdin Capital, Alexandria Venture Investments and other undisclosed investors.

Led by Charles Homcy, M.D., founder and interim chief executive officer of Maze and a partner at Third Rock Ventures, the company’s scientific founders are:
– Mark Daly, Ph.D., a pioneer in the field of human genetics. Dr. Daly is a co-director of the Program in Medical and Population Genetics at the Broad Institute, founding chief of the Analytic and Translational Genetics Unit at Massachusetts General Hospital, and director of the Institute for Molecular Medicine Finland.
– Stephen Elledge, Ph.D., a leader in the field of genetics. Dr. Elledge is the Gregor Mendel Professor of Genetics and Medicine at Harvard Medical School and Brigham and Women’s Hospital; an investigator at the Howard Hughes Medical Institute; and is a recipient of the Lasker Award, Gairdner International Award and The Breakthrough Prize in Life Sciences.
– Aaron Gitler, Ph.D., a neuroscientist and genetics expert whose work has focused on understanding the cellular consequences of protein misfolding to suggest potential strategies for therapeutic intervention. Dr. Gitler is a professor of genetics at Stanford University.
– Sekar Kathiresan, M.D., a renowned physician-scientist and human geneticist who is focused on the genetics of complex diseases. Dr. Kathiresan is director of the Center for Genomic Medicine at Massachusetts General Hospital; director of the Cardiovascular Disease Initiative at the Broad Institute; and professor of medicine at Harvard Medical School.
– Jonathan Weissman, Ph.D., widely recognized for building innovative tools to interrogate the organizational principals of biological systems. He is a professor and vice chair of the Department of Cellular & Molecular Pharmacology at the University of California, San Francisco and investigator at the Howard Hughes Medical Institute.

The Maze leadership team is also comprised of:
– Tim Behrens, M.D., senior vice president, human genetics;
– Matthew Brauer, Ph.D., vice president, data science;
– Jason Coloma, Ph.D., chief operating officer;
– Jeffrey Finer, M.D., Ph.D., chief technology officer;
– Eric Green, M.D., Ph.D., vice president,
– R&D David Morgans, Ph.D., senior vice president, drug discovery; and
– Tara Nickerson, Ph.D., chief business officer.



Join the discussion